All medicines, including veterinary medicines, carry benefits and risks. NexGard® and NexGard SPECTRA® contain the active ingredient afoxolaner. Afoxolaner is part of the isoxazoline family of chemicals. Adverse reactions to this family of chemicals are rarely observed but may include vomiting, diarrhoea, lethargy, inappetence (loss of appetite), itching and very rarely, seizures. Most adverse reactions are mild, self-limiting and of short duration. For dogs with a history of epilepsy or other seizure disorders, it is recommended to seek veterinary advice prior to treatment with medicines of this class. Milbemycin oxime, the other active ingredient in NexGard SPECTRA, is part of the macrocyclic lactone family of chemicals. Adverse reactions to milbemycin oxime are rarely observed at recommended doses.
Rigorous safety studies demonstrate NexGard and NexGard SPECTRA’s excellent safety profile. This is further supported by Boehringer Ingelheim’s rigorous pharmacovigilance program which closely monitors and evaluates any suspected adverse events reported to the company by pet owners or veterinarians in all countries where the product is registered.
For more information please read the product information leaflets . If you have any questions or concerns about NexGard or NexGard SPECTRA, we encourage you to contact your Veterinarian or Boehringer Ingelheim Animal Health Customer Care directly on 1800 808 691.
Copyright and Trademark Notice